Smokers and other people at high risk for lung cancer could make matters worse if they take antioxidant supplements, a new study of rodents suggests. Antioxidants appear to accelerate cancer progression by short-circuiting one of the ...
Tags: antioxidants, health, Cancer
Current guidelines are more detailed regarding some aspects of treatment On 3 January 2014 the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical ...
Americans are living longer than ever and their life expectancy is increasing every year, federal health officials reported Monday. People born in 2009 can expect to live 78.5 years. That's an increase from just a year before (when life ...
Tags: Americans, living longer, life expectancy, CDC
Electromed, Inc. (NYSE MKT: ELMD), a global medical device company, today announced it has received notification from the U.S. Food and Drug Administration that its next generation SmartVest® Airway Clearance System, the model ...
Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients, announced today that its investor group and employee shareholders ...
Tags: Ikaria, sell the Commercial Business, Madison Dearborn Partners
Cancer death rates continue to decline in the United States, mainly because anti-smoking efforts have caused a drop in lung cancer deaths, researchers report. From 2001 through 2010, death rates for all cancers combined decreased by 1.8 ...
Tags: cancer death rates, US, anti-smoking efforts
Anoro Ellipta (umeclidinium and vilanterol inhalation powder) has been approved by the U.S. Food and Drug Administration for once-daily treatment of chronic obstructive pulmonary disease (COPD). COPD, an umbrella term that includes the ...
Tags: Anoro Ellipta
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline (GSK) and Theravance's Anoro Ellipta as a once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease ...
GlaxoSmithKline (GSK) and Theravance have received marketing authorization from the European Commission (EC) for their jointly-developed asthma and chronic obstructive pulmonary disease (COPD) drug 'Relvar Ellipta'. Relvar, which is a ...
Tags: GSK, Relvar Ellipta
UK-based GlaxoSmithKline (GSK) and US-based Theravance have announced the availability of BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), in the US pharmacies. BREO ELLIPTA is a ...
Pulmatrix has released positive results from initial stage of Phase IB clinical trial of a bronchodilator therapy PUR0200 for patients with chronic obstructive pulmonary disease (COPD). The company said PUR0200 is the first small molecule ...
Boehringer Ingelheim has obtained marketing approval for Striverdi Respimat (olodaterol), a long-lasting bronchodilator indicated for chronic obstructive pulmonary disease (COPD), in the UK, Denmark and Iceland. This approval is based ...
GlaxoSmithKline and biopharmaceutical company Theravance have announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for fluticasone furoate/vilanterol ...
The Pulmonary-Allergy Drugs Advisory Committee (PADAC) of the US Food and Drug Administration (FDA) has recommended the approval of GlaxoSmithKline (GSK) and Theravance's umeclidinium/vilanterol as a treatment for chronic obstructive ...
Tags: Health, Medicine, Investigational Copd Drug
One of the world's top-selling drugs—GlaxoSmithKline PLC's $8-billion-a-year asthma treatment Advair—became more vulnerable to generic competition after the U.S. Food and Drug Administration issued guidance on the regulatory ...